Literature DB >> 2364376

Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.

D M Woodcock1, S Jefferson, M E Linsenmeyer, P J Crowther, G M Chojnowski, B Williams, I Bertoncello.   

Abstract

A polyethoxylated castor oil, Cremophor EL, which is used as a vehicle for p.o. and i.v. administration of water-insoluble compounds in humans, can reverse the multidrug resistance (MDR) phenotype at doses which are likely to be readily achievable clinically. Using flow cytofluorometric analysis of daunorubicin (DNR) uptake as a measure of the expression of the MDR phenotype, Cremophor EL (1:10(3] in the growth medium increased intracellular DNR in an MDR cell line, R100 cells, to levels similar to that observed in the drug-sensitive parental cells, CCRF-CEM. A similar Cremophor EL-induced increase in DNR uptake was also observed in an unrelated MDR cell line derived from K562 cells. Cremophor EL (less than or equal to 3:10(4] did not inhibit the growth of CCRF-CEM cells or its vinblastine-resistant derivative, R100 cells, but would significantly increase the sensitivity of R100 cells to both vinblastine and DNR. Also Cremophor EL did not increase the sensitivity of normal bone marrow progenitor cells cultured in vitro to high concentrations of vinblastine. Cremophor EL may prove to be a relatively pharmacologically inactive addition to chemotherapeutic protocols which may be able to reverse the MDR phenotype in tumors and also help to prevent the selection of MDR cell variants from within a tumor cell population during chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2364376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 2.  Tubulin interacting agents: novel taxanes and epothilones.

Authors:  Neeraj R Agrawal; Ram Ganapathi; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

3.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

4.  Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.

Authors:  K Osann; P Sweet; L M Slater
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Cytotoxicity of fractionated paclitaxel (Taxol) administration in vitro.

Authors:  L Plasswilm; N Cordes; R Fietkau; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-01       Impact factor: 3.621

6.  Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis.

Authors:  H H Boer; C M Moorer-van Delft; L J Müller; B Kiburg; J B Vermorken; J J Heimans
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.

Authors:  Ta-Chung Chao; Zyting Chu; Ling-Ming Tseng; Tzeon-Jye Chiou; Ruey-Kuen Hsieh; Wei-Shu Wang; Chueh-Chuan Yen; Muh-Hwa Yang; Liang-Tsai Hsiao; Jin-Hwang Liu; Po-Min Chen
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

8.  Methylation and expression of a metallothionein promoter ovine growth hormone fusion gene (MToGH1) in transgenic mice.

Authors:  K J Snibson; D Woodcock; J M Orian; M R Brandon; T E Adams
Journal:  Transgenic Res       Date:  1995-03       Impact factor: 2.788

Review 9.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  GM-144, a novel lipophilic vaginal contraceptive gel-microemulsion.

Authors:  O J D'Cruz; S H Yiv; F M Uckun
Journal:  AAPS PharmSciTech       Date:  2001-04-09       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.